相关实验视频

Updated: Jul 24, 2025

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles

Published on: January 26, 2024

第一个三个月的母体血蛋白质组变化预测自发的中度/晚期早产

Danai Mavreli¹, Mariana Theodora², George Lambrou³

¹Laboratory of Medical Genetics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians

|July 10, 2023

概括

研究人员在第一季度母亲血中鉴定出236种差异表达蛋白 (DEPs),与凝血和补充通路有关,在后来经历自发中度/晚期早产 (sPTD) 的女性中. 证实了VCAM-1,SAA和Talin-1的水平降低是sPTD的潜在预测生物标志物.

科学领域:

蛋白质组学是指蛋白质组学.
生物标志物发现发现
孕产妇和胎儿医学孕产妇和胎儿医学

背景情况:

过早分娩 (PTD) 仍然是新生儿发病率和死亡率的主要原因.
确定可靠的生物标志物来预测怀孕早期自发中度/晚期PTD (sPTD) 对于及时干预至关重要.
目前的诊断方法缺乏足够的预测准确性为sPTD.

研究的目的:

为了确定与随后的自发中度/晚期早产 (sPTD) 相关的第一季度母亲血中的差异表达蛋白 (DEPs).
探索这些DEP作为预测性生物标志物的潜力,用于妊娠32至36周之间发生的sPTD.

主要方法:

使用等离子标签进行相对和绝对量化 (iTRAQ) 的蛋白质组分析,加上液体染色学-并联质谱法 (LC-MS/MS).
对怀孕第一季度的母体血样本进行分析.
在一个独立的队列中,使用酶相关免疫吸收试验 (ELISA) 验证选定蛋白质表达水平.

主要成果:

在第一季度母亲血中鉴定了236个DEP,这些女性随后患有sPTD.
DEP主要与凝血和补充级联途径有关.
血管细胞粘附分子-1 (VCAM-1),血清粉样蛋白A (SAA) 和Talin-1的降低水平被ELISA证实,表明它们作为sPTD预测生物标志物的潜力.

结论:

第一个三个月的母体血蛋白质组分析显示了与随后的中度/晚期自发早产相关的显著蛋白质变化.
VCAM-1,SAA和Talin-1显示出作为sPTD早期预测生物标志物的承诺.
这些发现有助于开发用于早期发现和管理早产的新策略.

关键词:

时间提前交付 (PTD)生物标志物生物标志物早期预测早期预测蛋白质组学蛋白质组学自发性早产 (sPTD) 是一种

更多相关视频

The 4-vessel Sampling Approach to Integrative Studies of Human Placental Physiology In Vivo

The 4-vessel Sampling Approach to Integrative Studies of Human Placental Physiology In Vivo

Published on: August 2, 2017

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Published on: November 20, 2015

相关概念视频

Teratogenicity

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...